{"id":"allo-apz2-cvu","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL472440","moleculeType":"Small molecule","molecularWeight":"262.30"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The exact mechanism of action of allo-APZ2-CVU is not well understood, but it is believed to modulate the CVU receptor, leading to therapeutic effects.","oneSentence":"Allo-APZ2-CVU is a small molecule that targets the CVU receptor.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:44:20.762Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atrial fibrillation for stroke prevention"}]},"trialDetails":[{"nctId":"NCT04971161","phase":"PHASE2","title":"Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of CVU (Phase IIb)","status":"COMPLETED","sponsor":"RHEACELL GmbH & Co. KG","startDate":"2021-08-18","conditions":"Skin Ulcer Venous Stasis Chronic","enrollment":159},{"nctId":"NCT06489028","phase":"PHASE3","title":"Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Therapy-resistant CVU (Phase III)","status":"ACTIVE_NOT_RECRUITING","sponsor":"RHEACELL GmbH & Co. KG","startDate":"2024-12-26","conditions":"Venous Leg Ulcer","enrollment":250},{"nctId":"NCT03257098","phase":"PHASE1, PHASE2","title":"Allogeneic ABCB5-positive Stem Cells for Treatment of CVU","status":"COMPLETED","sponsor":"RHEACELL GmbH & Co. KG","startDate":"2017-11-16","conditions":"Skin Ulcer Venous Stasis Chronic","enrollment":31}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Skin-derived ABCB5-positive dermal mesenchymal stromal cells"],"phase":"phase_3","status":"active","brandName":"allo-APZ2-CVU","genericName":"allo-APZ2-CVU","companyName":"RHEACELL GmbH & Co. KG","companyId":"rheacell-gmbh-co-kg","modality":"Biologic","firstApprovalDate":"","aiSummary":"Allo-APZ2-CVU is a small molecule that targets the CVU receptor. Used for Atrial fibrillation for stroke prevention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}